Bifurcated monocyte states are predictive of mortality in severe COVID-19

Anthony R Cillo1,2, Ashwin Somasundaram1,2, Feng Shan1,2,3

  • 1Department of Immunology, School of Medicine, University of Pittsburgh. Pittsburgh, PA 15260, USA.

Insights

Monocyte immune cells show distinct genomic states linked to survival or death in severe COVID-19 patients. Identifying these states may help develop new diagnostics and treatments for critical coronavirus disease 2019.

Area of Science:

  • Immunology
  • Genomics
  • Infectious Diseases

Background:

  • Severe Coronavirus disease 2019 (COVID-19) presents diverse clinical outcomes, including high mortality from acute respiratory distress syndrome (ARDS).
  • Understanding the specific immune cell states driving mortality in severe COVID-19 is crucial for developing targeted therapies.
  • Existing research necessitates further delineation of immune cell contributions to fatal COVID-19 outcomes.

Approach:

  • High-dimensional cellular and molecular profiling of blood and respiratory samples from critically ill COVID-19 patients.
  • Utilized single-cell RNA sequencing (scRNAseq) to deconvolve genomic states of peripheral immune cells.
  • Employed machine learning algorithms to identify immune cell states predictive of COVID-19 mortality.

Key Points:

  • Critically ill patients exhibited increased inflammatory monocytes and plasmablasts, also seen in non-COVID-19 ARDS.
  • Monocytes displayed bifurcated genomic states: a cytokine module (e.g., CCL4) linked to survival and an interferon module linked to death.
  • These monocyte states, correlating with plasma cytokine levels (MIP-1β, CXCL10), were detectable in respiratory samples and predicted mortality.

Conclusions:

  • Monocytes play a pivotal role in COVID-19 mortality through specific inflammatory genomic states.
  • Distinct monocyte genomic profiles can serve as biomarkers for predicting COVID-19 patient outcomes.
  • Findings may guide the development of novel diagnostics and therapeutics for severe COVID-19.